Document 0558
 DOCN  M9440558
 TI    Liposomal doxorubicin for treatment of AIDS-related Kaposi's sarcoma.
 DT    9404
 AU    Simpson JK; Miller RF; Spittle MF; Meyerstein Institute of Clinical
       Oncology, Middlesex Hospital,; London, UK.
 SO    Clin Oncol (R Coll Radiol). 1993;5(6):372-4. Unique Identifier :
       AIDSLINE MED/94137636
 AB    Sixteen patients with advanced AIDS-related Kaposi's sarcoma received
       liposomal doxorubicin (Doxil, Liposome Technology, Menlo Park,
       California) at 20 mg/m2 every 2 or 3 weeks in an open label study, and
       were evaluated for efficacy and toxicity. Eleven patients achieved a
       partial remission and five had stable disease. The median time to
       achieve a maximum response was two cycles (range 1-3) and the median
       duration of response was 14 weeks (range 6-30). Myelosuppression was the
       commonest adverse event; one patient was withdrawn because of
       neutropenia. Other adverse events were uncommon and mild. Liposomal
       doxorubicin is an effective and safe single agent treatment for advanced
       AIDs-related Kaposi's sarcoma.
 DE    Acquired Immunodeficiency Syndrome/*COMPLICATIONS  Adult
       Alopecia/CHEMICALLY INDUCED  Doxorubicin/*ADMINISTRATION &
       DOSAGE/ADVERSE EFFECTS  Drug Carriers  Follow-Up Studies  Hematologic
       Diseases/CHEMICALLY INDUCED  Human  Liposomes  Male  Middle Age
       Nausea/CHEMICALLY INDUCED  Sarcoma, Kaposi's/*DRUG THERAPY/ETIOLOGY
       Treatment Outcome  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).